<p>Background: Dupilumab was equally effective among all racial subgroups in clinical trials, but a direct comparison in daily practice is lacking. Objectives: To investigate the effectiveness of dupilumab in patients with atopic dermatitis (AD) in the Netherlands and Japan over 80 weeks of treatment. Methods: A longitudinal comparative cohort study was conducted in patients with AD who were treated with dupilumab in daily practice. We used linear mixed-effects models to determine changes over time. Results: We found statistically significant differences in sex, disease onset, body mass index and therapeutic history between Dutch (n = 208) and Japanese (n = 153) patients. The baseline Eczema Area and Severity Index (EASI) score was higher in Japanese patients (23·8 vs. 14·8), while baseline Patient-Reported Outcome Measures (PROMs) were higher in Dutch patients. EASI scores decreased quickly to a level indicating ‘mild disease’ (EASI &lt; 7), and remained low in both countries. However, PROMs showed different trajectories with better scores in Japan. Conclusions: Dupilumab showed significant, comparable and sustained improvement of EASI scores in Japanese and Dutch patients. However, we found striking differences in the effect on PROMs between the countries, with a better outcome in Japanese patients.</p>

doi.org/10.1111/bjd.19897, hdl.handle.net/1765/136223
British Journal of Dermatology
Erasmus MC: University Medical Center Rotterdam

L.E.M. (Linde) de Wijs, R. F.T. Fujimoto, E.R. (Elrozy) Andrinopoulou, T.E.C. (Tamar) Nijsten, D. (Dirk Jan) Hijnen, & Y Kataoka. (2021). Dupilumab treatment in patients with atopic dermatitis. British Journal of Dermatology, 185(3), 555–562. doi:10.1111/bjd.19897